Gsk3772701

Phase 2

GSK

Gsk3772701 is one of 3 therapeutic programs targeting Malaria, Falciparum. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Malaria, FalciparumNot yet recruiting

Malaria, FalciparumPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Malaria, Falciparum

#DrugCompanyPhaseTrials

Aralen

Sanofi

Approved

1 2

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 3

Gsk3772701

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Malaria, Falciparum

NCT07545681

Clinical

Trials by Indication[1]

Malaria, Falciparum2 trials

A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 55 Years to Investigate the CYP3A4 Interaction Potential of GSK3772701

Recruiting· GSK logo

GSK·Phase 1·NCT07670377·20 enrolled

A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07545681·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gsk3772701. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gsk3772701. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: GSK

Gsk3772701

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Malaria, Falciparum2 trials

References

Drug Info

Quick Facts

Related News